Evidence map›Paper›PMID 21411865›Full record

ArticleOncotarget2011

APC +/- alters colonic fibroblast proteome in FAP.

Bhavinkumar B Patel, Xin-Ming Li, Maketa P Dixon, Elena L Blagoi, Emmanuelle Nicolas, Steven H Seeholzer, David Cheng, Yin A He, Renata A Coudry, Sharon D Howard and 9 more

Open access · hybridAbstract read
In one paragraph

Article in Oncotarget, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 19 citations in OpenAlex.

  1. Colon fibroblasts from Pirc rats (F344/NTac-ApcInternational journal of cancer · 2022
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Heritable one-hit events defining cancer prevention?Cell cycle (Georgetown, Tex.) · 2013
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 1 country.

Bhavinkumar B PatelDevelopmental Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
Xin-Ming Li
Maketa P Dixon
Elena L Blagoi
Emmanuelle Nicolas
Steven H Seeholzer
David Cheng
Yin A He
Renata A Coudry
Sharon D Howard
Dawn M Riddle
Harry C Cooper
Bruce M Boman
Peggy Conrad
James A Crowell
Alfonso Bellacosa
Alfred Knudson
Anthony T Yeung
Levy Kopelovich
Fox Chase Cancer Center · USNational Cancer Institute · USThomas Jefferson University · USUniversity of California, San Francisco · US

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Margaret von Mehren · 1985 to 2026
$138.8M
The MED1 Protein in DNA Damage Response and RepairR01CA078412 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI BELLACOSA, ALFONSO · 2004 to 2014
$3.7M
Proteomic Analyses for GI Stem Cell Markers &MechanismsR21DK063014 · NIDDK · THOMAS JEFFERSON UNIVERSITY · PI BOMAN, BRUCE M · 2003 to 2004
$356k
Proteomic Biomarkers in Pancreatic Cyst FluidsR03CA119242 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI YEUNG, ANTHONY T · 2005 to 2006
$169k
NEW APPROACHES TO ANALYSIS OF BIOPOLYMERSR01CA043309 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI VARSHAVSKY, ALEXANDER J · 1986 to 1990
–
PHASE I CLINICAL STUDIES OF CHEMOPREVENTIVE AGENTS - WS 40 -261015103N01CN015103 · CN · FOX CHASE CANCER CENTER · 2004 to 2004
–
PHASE I CLINICAL STUDIES OF CHEMOPREVENTIVE AGENTS - WS 40-261015103N01CA015103 · NCI · FOX CHASE CANCER CENTER · 2002 to 2003
–
NCI NIH HHS CA119242NCI NIH HHS N01 CN015103NCI NIH HHS N01 CN043309NCI NIH HHS N01-CN-15103NCI NIH HHS N01-CN-43309NCI NIH HHS P30 CA006927NCI NIH HHS P30CA006927NCI NIH HHS R01 CA078412NCI NIH HHS R03 CA119242NIDDK NIH HHS DK063014NIDDK NIH HHS R21 DK063014
6 · The paper itself

Abstract

Here we compared the proteomes of primary fibroblast cultures derived from morphologically normal colonic mucosa of familial adenomatous polyposis (FAP) patients with those obtained from unaffected controls. The expression signature of about 19% of total fibroblast proteins separates FAP mutation carriers from unaffected controls (P < 0.01). More than 4,000 protein spots were quantified by 2D PAGE analysis, identifying 368 non-redundant proteins and 400 of their isoforms. Specifically, all three classes of cytoskeletal filaments and their regulatory proteins were altered as were oxidative stress response proteins. Given that FAP fibroblasts showed heightened sensitivity to transformation by KiMSV and SV40 including elevated levels of the p53 protein, events controlled in large measure by the Ras suppressor protein-1 (RSU-1) and oncogenic DJ-1, here we show decreased RSU1 and augmented DJ-1 expression in both fibroblasts and crypt-derived epithelial cells from morphologically normal colonic mucosa of FAP gene-carriers. The results indicate that heterozygosity for a mutant APC tumor suppressor gene alters the proteomes of both colon-derived normal fibroblasts in a gene-specific manner, consistent with a "one-hit" effect.

Indexed as

Genes, APCAdenomatous Polyposis ColiAdultAgedCase-Control StudiesFibroblastsGene Expression Regulation, NeoplasticHeterozygoteHumansIntracellular Signaling Peptides and ProteinsMiddle AgedNeoplasm ProteinsOncogene ProteinsOxidative StressProtein Deglycase DJ-1ProteomeIntracellular Signaling Peptides and ProteinsNeoplasm ProteinsOncogene ProteinsPARK7 protein, humanProtein Deglycase DJ-1ProteomeRSU1 protein, humanTranscription Factors

Identifiers

PMID21411865
PMCPMC3195363
OpenAlexW2100058584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.